Depth of Neuromuscular Blockade and the Perioperative Conditions in Laparoscopic Surgery in Pediatric Population

NACompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

September 30, 2018

Study Completion Date

May 31, 2019

Conditions
Neuromuscular Blockade
Interventions
DRUG

Rocuronium

rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)

DRUG

Cisatracurium

cisatracurium 0.15mg/kg intravenously

DRUG

Nonspecific Neuromuscular Blockade reversal

neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously

DRUG

Specific Neuromuscular Blockade reversal

Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered

DRUG

maintaining the depth of neuromuscular blockade - rocuronium

repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1

DRUG

maintaining the depth of neuromuscular blockade - cisatracurium

repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1

Trial Locations (1)

62500

University Hospital Brno - FN Brno, Brno

All Listed Sponsors
collaborator

KDCHOT FN Brno

UNKNOWN

lead

Brno University Hospital

OTHER

NCT02546843 - Depth of Neuromuscular Blockade and the Perioperative Conditions in Laparoscopic Surgery in Pediatric Population | Biotech Hunter | Biotech Hunter